Linezolid for infective endocarditis: A structured approach based on a national database experience.
dc.contributor.author | Muñoz, P | |
dc.contributor.author | De la Villa, S | |
dc.contributor.author | Martínez-Sellés, M | |
dc.contributor.author | Goenaga, M A | |
dc.contributor.author | Reviejo-Jaka, K | |
dc.contributor.author | Revillas, F Arnáiz de Las | |
dc.contributor.author | García-Cuello, L | |
dc.contributor.author | Hidalgo-Tenorio, C | |
dc.contributor.author | Rodríguez-Esteban, M A | |
dc.contributor.author | Antorrena, I | |
dc.contributor.author | Castelo-Corral, L | |
dc.contributor.author | García-Vázquez, E | |
dc.contributor.author | De la Torre, J | |
dc.contributor.author | Bouza, E | |
dc.contributor.author | Spanish Collaboration on Endocarditis- Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) | |
dc.date.accessioned | 2025-01-07T14:32:02Z | |
dc.date.available | 2025-01-07T14:32:02Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Current data on the frequency and efficacy of linezolid (LNZ) in infective endocarditis (IE) are based on small retrospective series. We used a national database to evaluate the effectiveness of LNZ in IE.This is a retrospective study of IE patients in the Spanish GAMES database who received LNZ. We defined 3 levels of therapeutic impact: LNZ 50% of the total treatment, and > 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ | |
dc.identifier.doi | 10.1097/MD.0000000000027597 | |
dc.identifier.essn | 1536-5964 | |
dc.identifier.pmc | PMC8701757 | |
dc.identifier.pmid | 34941026 | |
dc.identifier.pubmedURL | https://pmc.ncbi.nlm.nih.gov/articles/PMC8701757/pdf | |
dc.identifier.unpaywallURL | https://doi.org/10.1097/md.0000000000027597 | |
dc.identifier.uri | https://hdl.handle.net/10668/26476 | |
dc.issue.number | 51 | |
dc.journal.title | Medicine | |
dc.journal.titleabbreviation | Medicine (Baltimore) | |
dc.language.iso | en | |
dc.organization | SAS - Hospital Universitario Virgen de las Nieves | |
dc.organization | SAS - Hospital Costa del Sol | |
dc.page.number | e27597 | |
dc.pubmedtype | Journal Article | |
dc.rights | Attribution-NonCommercial 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Anti-Bacterial Agents | |
dc.subject.mesh | Endocarditis | |
dc.subject.mesh | Endocarditis, Bacterial | |
dc.subject.mesh | Female | |
dc.subject.mesh | Hospital Mortality | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Linezolid | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Staphylococcal Infections | |
dc.subject.mesh | Staphylococcus aureus | |
dc.subject.mesh | Treatment Outcome | |
dc.title | Linezolid for infective endocarditis: A structured approach based on a national database experience. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 100 |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- PMC8701757.pdf
- Size:
- 252.67 KB
- Format:
- Adobe Portable Document Format